Lok Yi Lo
Gerontology · San Francisco, CANPI 1316665789
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,822 and has fallen 93.6% since, to $117 in 2025. Among gerontology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $32.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$517
- Lilly USA, LLC$275
- Eisai Inc.$212
- Merck$179
- Seagen Inc.$179
- E.r. Squibb & Sons, L.L.C.$175
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,10794%
- Education$1926%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 12 | $517 |
| Lilly USA, LLC | 7 | $275 |
| Eisai Inc. | 5 | $212 |
| Merck | 6 | $179 |
| Seagen Inc. | 5 | $179 |
| E.r. Squibb & Sons, L.L.C. | 3 | $175 |
| Regeneron Healthcare Solutions, Inc. | 4 | $110 |
| Bayer | 4 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $105 |
| Daiichi Sankyo Inc. | 4 | $100 |
| AbbVie | 4 | $94 |
| Legend Biotech USA Inc. | 1 | $93 |
| Pfizer | 3 | $93 |
| Johnson & Johnson | 3 | $92 |
| Blueprint Medicines Corporation | 3 | $88 |
| Geron Corporation | 1 | $82 |
| Novartis | 3 | $68 |
| Amgen | 3 | $67 |
| GSK | 2 | $57 |
| Octapharma USA, Inc. | 1 | $55 |
| Ipsen Biopharmaceuticals, Inc | 1 | $49 |
| Incyte Corporation | 2 | $45 |
| Rigel Pharmaceuticals, Inc. | 2 | $39 |
| Coherus Oncology, Inc. | 1 | $34 |
| Mirati Therapeutics, Inc. | 1 | $32 |
| Karyopharm Therapeutics Inc. | 1 | $31 |
| Puma Biotechnology, Inc. | 1 | $29 |
| Deciphera Pharmaceuticals Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $26 |
| CTI Biopharma Corp. | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Morphosys, US Inc. | 1 | $23 |
| Spectrum Pharmaceuticals Inc. | 1 | $23 |
| AVEO Pharmaceuticals, Inc. | 1 | $22 |
| Genmab U.S., Inc. | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Bristol Myers Squibb | 1 | $20 |
| Acrotech Biopharma Inc. | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,299 in reported general payments places this provider in the 90th percentile of 348 gerontology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 32 | $419,326 |
| JakafiRuxolitinib Phosphate | 16 | $368,312 |
| Neulasta OnproPegfilgrastim | 21 | $131,629 |
| Lupron DepotLeuprolide Acetate | 12 | $70,053 |
| AranespDarbepoetin Alfa In Polysorbat | 18 | $41,310 |
| EliquisApixaban | 19 | $17,171 |
| Entecavir | 11 | $5,690 |
| Leucovorin Calcium | 15 | $1,633 |
| Irinotecan Hcl | 24 | $1,446 |
| Ondansetron Hcl | 45 | $1,413 |
| Dexamethasone | 61 | $1,017 |
| Acyclovir | 23 | $444 |
| Prochlorperazine Maleate | 37 | $398 |
| Palonosetron Hcl | 13 | $396 |
| Mirtazapine | 24 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $110 | $419,32632 claims |
| Incyte CorporationJakafi | $45 | $368,31216 claims |
| AbbVieLupron Depot | $94 | $70,05312 claims |
| AmgenAranesp | $67 | $41,31018 claims |
| PfizerEliquis | $93 | $17,17119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 348 gerontology providers in California.
Other gerontology in San Francisco
- Lovely IsraelSanta Monica$95K
- Leslie TarlowLos Angeles$58K
- Christine PartamianPorter Ranch$41K
- Elsa Pineda-FloresLos Angeles$24K
- Maria MottaDuarte$23K
- Daniel ChiuOrange$17K
- Katiaryna KulinichChula Vista$15K
- Nataliya OsorioRiverside$13K
- Anne Marie de Joya ReeveDuarte$11K
- Wendy AlmonteLemoore$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.